Concord Biotech Ltd

Concord Biotech Bonus Issue

Concord Biotech's board recommended a 1:1 bonus share issue from free reserves. Shareholders will consider this proposal at an upcoming postal ballot on October 24, 2026.

Concord Biotech Bonus Issue

Concord Biotech approved a 1:1 bonus issue of 10.46 crore equity shares. The board also increased the company's authorized share capital to Rs. 22 Crore.

Value

₹10.46 Cr

Concord Biotech Board Meeting Date

Concord Biotech Ltd announced a board meeting for September 23, 2026, to consider a proposal for the declaration of bonus equity shares.

Concord Biotech Business Update

Concord Biotech disclosed a successful USFDA inspection at its Valthera facility with one minor non-GMP observation. No material impact on operations or existing supplies is expected.

Concord Biotech Earnings Call Transcript: Key Takeaways

Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.

Concord Biotech Investor Presentation: Key Takeaways

Concord Biotech reported strong Q1FY27 consolidated performance with 26% revenue growth and 31% PAT growth, driven by a 46% surge in exports and expanding market share in niche fermentation APIs.

Concord Biotech Q1 FY27 Results: Net Profit ₹57.7 Cr, Up 30.8% YoY

Concord Biotech Ltd reported revenue from operations of ₹257.5 Cr (+26.2% YoY) and net profit of ₹57.7 Cr (+30.8% YoY) for Q1 FY27.

Key figure

Net profit ₹57.7 Cr · +30.8% YoY

Concord Biotech Earnings Call: Key Takeaways

Concord Biotech reported a challenging FY26 with a 12% revenue decline and 30% PAT drop due to geopolitical headwinds, tender delays, and regulatory holdups. Management remains optimistic for a stronger FY27.

Concord Biotech Earnings Call: Key Takeaways

FY26 was a rough year marked by geopolitical disruptions and US procurement slowdowns. Management pivots to a recovery narrative for FY27, banking on new injectable facilities and US direct marketing to reverse recent de-growth.

Concord Biotech Earnings Call: Key Takeaways

Concord Biotech reported a challenging FY26 with consolidated revenue at ₹1,054.9 Cr (-12% YoY) and PAT at ₹259.2 Cr (-30% YoY) due to procurement delays and geopolitical issues.

Concord Biotech Q4 FY26 Results: Net Profit ₹88.5 Cr, Down 37.0% YoY

Concord Biotech Ltd reported revenue from operations of ₹326.1 Cr (-24.1% YoY) and net profit of ₹88.5 Cr (-37.0% YoY) for Q4 FY26.

Key figure

Net profit ₹88.5 Cr · -37.0% YoY